Characteristics and outcomes of patients with HER2-negative metastatic breast cancers with low expression of estrogen and progesterone receptors in the multicenter ESME cohort.

Fiche publication

Date publication

mai 2026

Journal

Breast (Edinburgh, Scotland)

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PETIT Thierry , Dr DESMOULINS Isabelle , Dr MASSARD Vincent

Tous les auteurs :
Alexandre M, Teruel E, Dalenc F, de la Motte Rouge T, Brain E, Massard V, Arnedos M, Mailliez A, Ferrero JM, Bachelot T, Desmoulins I, Mouret-Reynier MA, Levy C, Gonçalves A, Berghian A, Petit T, Frenel JS, Martin AL, Grinda T, Jacot W

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/42160910

Résumé

Breast cancers expressing low (1-9%) immunohistochemistry levels of estrogen and progesterone hormone receptors (HR), remain an uncertain category, being considered either as triple negative (TN) breast cancers or HR-positive (HR+) tumors across guidelines or approvals.